GSK plc
GSK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 1,048 institutions reported holding it in 13F filings for Q2 2026, worth $18.2B in total; no superinvestor holds it.
Other share classesGLAXF
Q2 2022 vs. Q1 2022
How the institutions holding GSK plc changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 930 | 6 | 902 | −22 |
| Shares | 331.6M | 3.02M | 340.4M | +11.9M (+3.6%) |
| Value | $14.4B | $138.7M | $15.7B | +$1.35B (+9.4%) |
6 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (105)
Institutions that held GSK plc at the end of Q2 2022 but not at the end of Q1 2022.
Showing the largest 100 of 105 by value.
Sold out (127)
Institutions that held GSK plc at the end of Q1 2022 and filed for Q2 2022 without it.
Showing the largest 100 of 127 by value.
Not filed for Q2 2022 yet (6)
Institutions that held GSK plc at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 2,803,032 | $122.1M |
| Majedie Asset Management Ltd | 187,150 | $8.13M |
| Holloway Wealth Management, LLC | – | $7.04M |
| Elevated Capital Advisors, LLC | 23,298 | $1.01M |
| American National Registered Investment Advisor, Inc. | 7,470 | $325.0K |
| Dixon Hughes Goodman Wealth Advisors LLC | 2,071 | $90.0K |